Label Changes for:
Increlex (mecasermin [rDNA origin]) injection
June 2012
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2012
ADVERSE REACTIONS
Post-Marketing Experience
- Skin and Subcutaneous Tissue Disorders: alopecia, hair texture abnormal

